BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS.
Herbaux C, et al. Among authors: tomowiak c.
Blood. 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303.
Blood. 2021.
PMID: 33598678
Free article.
Clinical Trial.